NRx Pharmaceuticals

NRXP · Nasdaq · United States

Share price · NRXP

$2.80-0.64 (-18.60%) 3M

close as of 2026-11-18 · 24h delayed · vol 2.2M (1.5x 30-day avg)

Loading chart…

Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento

Compare with peers →

Unusual price moves

Days when NRXP's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked

  1. 18 Nov 2026+14.3%
  2. 17 Nov 2026+14.0%
  3. 4 Nov 2026+11.2%
  4. 30 Oct 2026-14.7%
  5. 22 Oct 2026-8.7%

    Nothing announced by NRXP that day or the session before.

  6. 7 Aug 2026+15.9%
  7. 26 May 2026+33.9%

    Nothing announced by NRXP that day or the session before.

  8. 20 Apr 2026+25.5%

    Nothing announced by NRXP that day or the session before.

  9. 24 Mar 2026+20.3%
  10. 16 Mar 2026+11.8%

    Nothing announced by NRXP that day or the session before.

Share of unusual movement by asset

For each asset, the share of NRXP's own-move activity since 2 Jul 2024 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.

AssetEvent daysShare of unusual movement
Other company news (earnings, financing, releases naming no asset)—23%
Sessions with no dated event—77%

No dated announcements about its assets since 2 Jul 2024.

Assets

(1 total)
1Total Assets
0Approved
1Phase 3 / Filed
0Phase 1–2 / Early
2Diseases
Quick filter:
Showing 1 of 1 assets
Target & Modality
Phase 3
NMDA receptor (glycine site) + dopamine/5-HT receptorSmall molecule
Major Depressive DisorderBipolar Depression

Upcoming events

No upcoming trial completions or earnings dates on record for this company's assets.

Regulatory and conference events

(1)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

30 April 2024Topline resultNRX-101NRX-101 vs lurasidone Phase 2b/3 (NCT03395392) missed its primary endpoint
NRx Pharmaceuticals, Inc. · Source ↗

Financial reports

Quarterly & interim (15)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q2$1.1M$2.1M$27M$17M-$8.9M operating cash flowreport ↗
View 14 more
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q1$1.1M$1.3M—$1.4M-$4.3M operating cash flowreport ↗
2025-Q3$0.2M$1.4M—$5.9M-$2.9M operating cash flowreport ↗
2025-Q2—$1.0M—$18M-$4.0M operating cash flowreport ↗
2025-Q1$0$0.8M—$5.5M-$3.5M operating cash flowreport ↗
2024-Q3$0$0.6M—$1.6M-$2.3M operating cash flowreport ↗
2024-Q2—$2.8M—$7.9M-$2.6M operating cash flowreport ↗
2024-Q1—$1.8M$1.3M$6.5M-$3.7M operating cash flowreport ↗
2023-Q3—$3.3M$8.9M$6.1M-$4.6M operating cash flowreport ↗
2023-Q2—$3.9M$15M$8.7M-$7.8M operating cash flowreport ↗
2023-Q1—$3.6M$17M$11M-$6.1M operating cash flowreport ↗
2022-Q3—$4.1M$18M$9.1M-$6.3M operating cash flowreport ↗
2022-Q2—$3.0M$25M$7.0M-$15M operating cash flowreport ↗
2022-Q1—$5.5M$40M$13M-$10M operating cash flowreport ↗
2021-Q3—$6.3M$39M$21M-$12M operating cash flowreport ↗

Annual history (5 years)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2025-FY$1.2M$3.8M—$7.2M-$14M operating cash flowreport ↗

NRx Pharmaceuticals reported revenue of $1.23M for fiscal 2025 versus $0M in the prior year, with R&D spend of $3.78M, down 39.0% YoY. Cash and equivalents were not disclosed, and the company reported a net loss of $28.62M with a quarterly net burn of $28.62M.

The 10-K highlights clinical-stage CNS programs, including KETAFREE, for which the company received an FDA preliminary determination of no bioequivalence deficiency and plans to initiate commercial sales with FDA approval in Q3 2026; NRX-100, for which an NDA is expected to be filed in Q2 2026 under FDA Fast Track designation; and NRX-101, an oral candidate in development. The company also noted its role as founder and majority owner of HOPE Therapeutics, which provides interventional psychiatry care for treatment-resistant depression and PTSD.

View 4 more years
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2024-FY$0$6.2M—$6.3M-$11M operating cash flowreport ↗
2023-FY—$13M$4.6M$7.5M-$22M operating cash flowreport ↗
2022-FY—$17M$20M$9.9M-$40M operating cash flowreport ↗
2021-FY—$20M$28M$23M-$38M operating cash flowreport ↗

Insider transactions

Open-market activity, trailing 12 months: 0 purchases (—), 0 sales (—). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.

Source
2026-07-28Javitt Jonathan C · director, CEO and ChairmanAward / grant (derivative)150,000——Form 4
2026-07-28ABRAMS MICHAEL S · Chief Financial OfficerAward / grant (derivative)75,000——Form 4
2026-01-27Casper Joseph Michael · Chief Operating OfficerAward / grant (derivative)100,000——Form 4
2025-04-09Flynn Patrick John · directorAward / grant (derivative)50,000——Form 4
2025-04-09Hurvitz Chaim · directorAward / grant (derivative)25,000——Form 4
2025-04-09McBride Dennis · directorAward / grant (derivative)25,000——Form 4
2025-04-09Javitt Jonathan C · director, Chairman and Chief Scientist, 10% ownerAward / grant (derivative)125,000——Form 4
2025-02-07ABRAMS MICHAEL S · Chief Financial OfficerAward / grant (derivative)50,000——Form 4

Institutional holders

From SEC Form 13F filings for the quarter ended 2026-03-31 (filed up to 45 days later). 32 reporting institutions held 6.2M shares ($13.1M, 14.2% of shares outstanding).

#InstitutionSharesValue
1B Group, Inc.3,000,000$6.4M
2VANGUARD CAPITAL MANAGEMENT LLC1,160,184$2.5M
3AdvisorShares Investments LLC420,467$896K
4COMMONWEALTH EQUITY SERVICES, LLC397,431$847K
5GEODE CAPITAL MANAGEMENT, LLC310,112$661K
6VANGUARD FIDUCIARY TRUST CO169,580$361K
7Bleakley Financial Group, LLC117,204$250K
8BlackRock, Inc.98,995$211K
9STATE STREET CORP86,984$185K
10XTX Topco Ltd78,733$168K
11Chicago Partners Investment Group LLC34,479$102K
12JANE STREET GROUP, LLC44,152$94K
13NORTHERN TRUST CORP43,469$93K
14Headlands Technologies LLC39,394$84K
15AXQ CAPITAL, LP33,211$71K